Larotrectinib

Breastfeeding
  • TRADE NAME: Vitrakvi (Loxo Oncology Inc)
  • INDICATIONS: indicated for the treatment of adult and pediatric patients with solid tumors that:
    • have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a
    known acquired resistance mutation,
    • are metastatic or where surgical resection is likely to result in severe
    morbidity, and
    • have no satisfactory alternative treatments or that have progressed
    following treatment.
  • CLASS: Kinase inhibitor
  • HALF-LIFE: 2.9 hours

FDA APPROVAL DATE: 11/26/2018

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

None known

PREGNANCY CATEGORY: N/A
can cause embryo-fetal harm

Our database has 27 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
HEMATOLOGIC


Page last updated 11/28/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric